Navigation Links
Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
Date:9/24/2010

r practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Sept. 24, 2010 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
8. Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp(R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes
9. Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP
10. Amgen Highlights Data to be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
11. Amgen Board Authorizes $5 Billion Increase in Stock Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... --  Sigma-Aldrich Corporation (NASDAQ: SIAL ) a leading ... $50,000 product donation to the Reproducibility Project: Cancer ... from recent high-impact papers in the field of cancer ... research marketplace Science Exchange , the non-profit ... eLife. The goal of the project is ...
(Date:5/6/2015)... LONDON , May 6, 2015 ... HIV maintenance therapy with dolutegravir and rilpivirine ... start of a Phase III clinical trial programme ... (Tivicay®) and rilpivirine (Edurant® [1] ) as maintenance ... III programme comprises two replicate studies evaluating 48 ...
(Date:5/5/2015)... BARCELONA, Spain , May 6, 2015 ... and aspires to lead the European market in the ... Through this alliance ECUPHAR acquires all the assets ... the new organization in the coming weeks. Being both ... not been disclosed.      (Photo: http://photos.prnewswire.com/prnh/20150506/743274 ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10ECUPHAR Enters the Spanish and Southern European Markets Through ESTEVE 2
... SOUTH SAN FRANCISCO, Calif., March 2 Hana,Biosciences ... an Independent Data Monitoring,Committee (IDMC) has completed a ... ongoing pivotal rALLy clinical trial of Marqibo(R) (vincristine,sulfate ... lymphoblastic,leukemia (ALL) in second relapse. The results ...
... (ASX: PXS, Nasdaq: PXSL ) today announced ... the U.S. Food and Drug Administration (FDA) for Aridol, ... to help in the correct diagnosis and assessment of ... was based on a pre-NDA meeting with the FDA ...
Cached Medicine Technology:Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 2Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 3Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 4Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound 5Pharmaxis Announces New Drug Application Submission for Aridol(TM) 2Pharmaxis Announces New Drug Application Submission for Aridol(TM) 3
(Date:5/6/2015)... has opened press registration for TU-Automotive Detroit as the ... headlines of major publications world-wide. With 150+ speakers from ... to share their visions for the future of connected ... to go behind the scenes and hear major automakers’ ... year we’re releasing a preview of all the major ...
(Date:5/6/2015)... Water NSW (New South ... manage and distribute imagery, LiDAR, and Elevation Data within ... driest continents on earth, and the need to ensure ... erratic seasonal rainfalls has driven the development of several ... manages raw water supplies for NSW, including high quality ...
(Date:5/6/2015)... May 06, 2015 Cloud security companies ... announced a strategic partnership to help small-to-medium businesses secure ... two industry-leading companies are teaming up to transition SafeMonk ... , “We’re thrilled to welcome SafeMonk users to the ... the people behind SafeMonk, the global powerhouse SafeNet (now ...
(Date:5/6/2015)... 2015 National Physical Fitness and Sports ... within the U.S. Department of Health and Human Services ... Fitness and Sports Month. It is dedicated to ... to health. Throughout the month of May, Americans ... fit. , The HHS details the benefits of regular ...
(Date:5/6/2015)... 2015 Most people in the United States ... other care after age 65. But less than half of ... or even talking about it, reports the May 2015 ... two problems. One is losing control over the care they'll ... Dr. David Grabowski, a professor of health care policy at ...
Breaking Medicine News(10 mins):Health News:Press Registration for TU-Automotive Detroit Now Open 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 2Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 3Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2
... concern over discrepancies in official data for key sectors ... called for a revamp of the national statistical system ... the administrative set up and traditional records, the (statistical) ... changing times," Manmohan Singh said in his address at ...
... the Institute Pasteur has recently shown that the tuberculosis ... fat cells. //This formidable pathogen is protected against even ... it may remain dormant for years. ,This ... possible strategies for fighting tuberculosis. Attempts to eradicate the ...
... research centre is being planned at the Pune-based ... diseases//, a general says. ,"Stem cell therapy ... will be the futuristic treatment replacing drug therapy ... diabetes, Parkinson's disease, epilepsy, multiple sclerosis, eye and ...
... San Diego biologists have shown that the chemical language ... electrical activity in the developing nervous system. The findings ... as a treatment for a wide range of brain ... the early on-line edition of the journal Proceedings of ...
... Christmas is indeed a ‘ubiquitous’ festival, as it is celebrated ... an estimated 26 million Indian homes.// The joys of the ... are seen making the most of the special bargains and ... time for the celebration. Plans are afoot in great enthusiasm ...
... director of Clarkson's Center for Air Resources Engineering ... on airborne pollution who serves on the Environmental ... also one of scores of health officials and ... the casual link between pollutants and respiratory illnesses. ...
Cached Medicine News:Health News:Manmohan Calls for Statistical Reforms in Healthcare and Education 2Health News:Tuberculosis: The Bacillus Takes Refuge in Adipose Cells 2Health News:Military College to Set Up Stem Cell Research Centre 2Health News:Electrical Activity Alters Language Used By Nerve Cells 2Health News:Electrical Activity Alters Language Used By Nerve Cells 3Health News:Come Apart and Rest Awhile – It’s Christma 2Health News:Come Apart and Rest Awhile – It’s Christma 3Health News:Research on to Find Link Between Airborne Pollutants and Respiratory Illness 2
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
Liquichek Autoimmune Controls are individual controls for monitoring the performance of autoimmune assays....
... ACUSON brand, the new Antares system, ... system that provides highly upgradeable and ... workflow efficiencies, and user-friendly ergonomics. ,The ... upon the advanced workflow and diagnostic ...
Medicine Products: